Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

Published Results Also Show Potentially Differentiating Pharmacokinetic

Profile of Prodrug Stimulant

PHILADELPHIA, Nov. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that Biological Psychiatry published the results of a study showing VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 hours. The published study also found that VYVANSE demonstrated low interpatient variability of measured pharmacokinetic parameters, as reported by the coefficient of variance (%CV).

This phase II randomized, double-blind, placebo- and active-controlled crossover analog classroom study in children aged 6 to 12 examined the efficacy and safety of VYVANSE (30 mg, 50 mg or 70 mg) and Adderall XR (mixed amphetamine salts extended-release: 10 mg, 20 mg or 30 mg) compared with placebo.

"This newly published research shows that VYVANSE provided a consistent time to maximum plasma concentration from patient to patient," said Ann S. Childress, M.D., President of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, Nev. "This prodrug stimulant also demonstrated significant efficacy up to 12 hours after administration, which is something that my patients' parents are interested in as it may help to improve their family and homework time in the evening."

VYVANSE is a therapeutically inactive prodrug in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. Release of the active ingredient in VYVANSE does not rely on gastrointestinal factors such as gastrointestinal transit time and gastric pH.

Study Results Showed that VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation ... its CytoSorb® blood purification technology to help fight ... in 28 countries worldwide, today announced the appointment ... MD, FACS, as its Senior Vice President of ... Dr. Di Russo is an ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 2007 /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced the ... (R-Spondin1), a secreted protein currently in preclinical,development, ... and potent,stimulator of gastrointestinal (GI) epithelial cells. ... inflammatory bowel,conditions, including Crohn's disease and ulcerative ...
... DNA Therapeutics,S.A. an emerging pharmaceutical company specialized in ... new mechanism,of action and the identification of a ... will be,presented at the forecoming American Association for ... available online.,The presentation itself will be available from ...
Cached Medicine Technology:Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 2Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 3Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 4DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 2DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Molecules from cone snail venom and African plants are being ... oral drug to treat chronic pain. , Professor David ... Bioscience have received $218,275 from the National Health and Medical ... a product available for Australians to use. , Studies ...
... severe symptom reported by middle-aged women when their periods change ... study in the April issue of the UK-based Journal of ... of Nursing, USA, spoke to 110 women entering the menopause ... at longer or shorter intervals. Their average age was 49 ...
... RuiTai International Holdings Co., Ltd. (OTC Bulletin Board: ... and distributor,of cellulose ether products in the People,s ... for the fiscal year ended December,31, 2007., ... increased 36.7% to $38.4 million -- Gross ...
... Executive brings extensive experience in both healthcare and human ... ... 16 Precyse Solutions, the leader in,driving peak performance within Health ... Corporate,Vice President of Human Resources. She joins Precyse from Pegasus,Communications where ...
... next President to focus more on improving their,standard ... of jobs overseas than making it easier for ... to the latest "America At Work" national,opinion survey ... The workplace-issues poll, based on a sampling of ...
... It may produce chemicals that protect the brain, ... -- Regular physical exercise may help protect against ... study. , People with mild cognitive impairment can ... details of conversations, events and upcoming appointments. Most, ...
Cached Medicine News:Health News:Cone snails and plants used to develop oral drug for pain 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 2Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 4Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 5Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 6Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 7Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 8Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 9Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 3Health News:Exercise Could Cut Risk of Mild Cognitive Impairment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: